FGFR2 and breast carcinoma: In order to unravel the molecular mechanism of the p.K660N and another recently described somatic breast cancer mutation in FGFR2, p.R203C, we compared the tyrosine kinase activities of breast cancer mutants to that of wt FGFR2.